Giulia Rivoli

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

An Italian cartography of VEXAS-related thrombosis.

An Italian cartography of VEXAS-related thrombosis.

Journal: HemaSphere
Published: January 17, 2026

Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.

Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.

Journal: Annals of hematology
Published: March 27, 2025

Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort.

Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort.

Journal: British journal of haematology
Published: February 10, 2025

JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.

JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.

Journal: British journal of haematology
Published: December 09, 2024

Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.

Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.

Journal: British journal of haematology
Published: September 17, 2024

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

Journal: Blood cancer journal
Published: June 14, 2024

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.

Journal: Cells
Published: October 04, 2023

Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.

Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.

Journal: British journal of haematology
Published: August 28, 2023

Blastic plasmacytoid dendritic cell neoplasm: a short review and update.

Blastic plasmacytoid dendritic cell neoplasm: a short review and update.

Journal: Dermatology reports
Published: June 24, 2023

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 17, 2023

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Journal: American journal of hematology
Published: January 22, 2023

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

Journal: Blood advances
Published: February 12, 2020
Showing 1-12 of 16

Last Updated: 09/26/2026